UC Irvine Research Identifies Key Factor in Immunotherapy Resistance for Melanoma

A research team at the University of California, Irvine, has identified a primary reason why immunotherapy treatments often fail in patients with advanced melanoma. By integrating mathematics and biology, researchers developed a model that points to the speed at which specific immune cells, known as regulatory T cells or Tregs, infiltrate tumors as a critical factor in treatment resistance. These findings were published in the journal Cancer Research.

Immunotherapy treatments, particularly PD-1 blockade, have improved outcomes for many cancer patients by enabling the body’s immune system to identify and kill cancer cells. For patients with advanced melanoma, a highly aggressive form of skin cancer, these therapies have turned what were once terminal diagnoses into cases of long-term survival for some. However, approximately 7 out of 10 melanoma patients treated with PD-1 blockade immunotherapy experience disease recurrence, even after the treatment initially appeared to be effective.

Determining why immunotherapy loses efficacy and how to address this challenge has been a difficult and resource-intensive problem in cancer research. The conventional method involves testing one hypothesis at a time, a process that can take years and require significant funding. The UC Irvine team pursued a different strategy: constructing a mathematical model that captured key interactions between tumor and immune cells to identify the most probable mechanism of resistance before extensive laboratory experiments.

Within a tumor, effector T cells are the immune system’s primary weapon, actively seeking out and destroying malignant cells. Regulatory T cells (Tregs) serve a different purpose; they normally restrain the immune system from mistakenly attacking healthy tissue. In the context of cancer, however, Tregs can end up protecting the tumor by suppressing the effector T cells that should be fighting it. Tumor cells add another layer of defense by displaying a protein called PD-L1 on their surface. This protein binds to a receptor called PD-1 on effector T cells, sending an inhibitory signal that shuts down their activity. PD-1 blockade immunotherapy thwarts this interaction, thereby reactivating effector T cells. However, this treatment can also have an unintended consequence: it can simultaneously strengthen Treg activity, helping to restore the immunosuppressive environment it was designed to overcome.

The UC Irvine researchers translated these complex cellular interactions into a system of mathematical equations, grounded in decades of published cancer research. They validated this model against experimental data from mice with melanoma, refining its predictions until they aligned with observed outcomes. With sufficient accuracy, the team then used the model to generate 342 “virtual mice” with melanoma—computational simulations in which each behaved somewhat differently, reflecting the natural biological variation observed across a real population.

Simulating PD-1 blockade immunotherapy across these virtual mice, the researchers compared those that responded favorably with those that experienced disease recurrence. Among more than 30 biological parameters incorporated into the model, the speed at which Tregs were entering the tumor emerged as the most consistent distinguishing factor between the two groups. Rachel Sousa, the study’s first author and a graduate student researcher, stated that the mathematical analysis “indicated that the rate of Treg infiltration into the tumor was the critical factor.”

To confirm the model's prediction experimentally, the team engineered mice where Tregs migrated inefficiently into tumors, while the rest of the immune system remained intact. Treating these animals with PD-1 blockade immunotherapy combined with reduced Treg migration substantially outperformed PD-1 blockade alone. This combined intervention nearly doubled survival duration and slowed tumor growth in mice whose cancer was not fully eliminated. John Lowengrub, a Distinguished Professor of mathematics and co-senior investigator, noted that the agreement between the model prediction and experiments “validates our approach” and identifies critical targets for improving cancer treatment.

This study does not represent an immediately available treatment for patients but offers a faster, more cost-efficient framework for identifying promising therapeutic strategies. Instead of spending several years and millions of dollars investigating dozens of potential mechanisms of drug resistance sequentially, researchers now have a tool capable of narrowing the field of candidates before any large-scale experimental studies are initiated. Francesco Marangoni, an assistant professor of physiology and biophysics and one of the study’s senior investigators, noted that the team “integrated two entirely distinct disciplines – mathematics and biology” to inform one another.

For melanoma specifically, this research reinforces interest in a therapeutic strategy already under exploration: simultaneously targeting Treg infiltration of the tumor while employing PD-1 blockade immunotherapy. Earlier attempts at Treg inhibition were complicated by off-target effects on beneficial immune cells. This study indicates that more selective interventions, specifically targeting only the tumor-protective Treg population, could be a more promising direction for future clinical investigation. Equally significant, the mathematical model itself is a reusable platform for testing the efficacy of other treatments individually or in combination, and can be utilized to explore other mechanisms of therapy resistance.